BACKGROUND/AIMS: Longer exposure to hepatitis C (HCV) or B virus (HBV) and the increased use of hepatitis treatment might have an impact on liver-related deaths in patients co-infected with the Human Immunodeficiency Virus (HIV). We describe the proportion of liver-related deaths among HIV-infected patients in 2005 compared with 2000. METHODS: In a nationwide survey (341 hospital departments involved in HIV management), all deaths of HIV-infected patients were prospectively reported. Deaths from either cirrhosis, hepatocellular carcinoma or fulminant hepatitis were defined as liver-related deaths. RESULTS: Of the 898 deaths reported in 2005, liver-related causes accounted for 15.4%; this is compared to 13.4% in 2000. Among liver-related deaths, hepatocellular carcinoma increased from 15% to 25% (p=0.04). Among hepatocellular carcinoma-related deaths: in 2000, 10% were HCV-infected; in 2005, 25% were HCV-infected (p=0.03). Half of the HCV-related deaths had been treated for HCV but 98% remained HCV-RNA positive at time of death. The proportion of HBV-related deaths remained stable between 2000 and 2005. CONCLUSIONS: Liver-related deaths, mainly liver cancers, have increased in HIV-infected patients in France despite wide access to HCV treatment. The stability of HBV-related deaths might be explained by the use of dually active antiretroviral drugs in co-infected patients.
BACKGROUND/AIMS: Longer exposure to hepatitis C (HCV) or B virus (HBV) and the increased use of hepatitis treatment might have an impact on liver-related deaths in patients co-infected with the Human Immunodeficiency Virus (HIV). We describe the proportion of liver-related deaths among HIV-infectedpatients in 2005 compared with 2000. METHODS: In a nationwide survey (341 hospital departments involved in HIV management), all deaths of HIV-infectedpatients were prospectively reported. Deaths from either cirrhosis, hepatocellular carcinoma or fulminant hepatitis were defined as liver-related deaths. RESULTS: Of the 898 deaths reported in 2005, liver-related causes accounted for 15.4%; this is compared to 13.4% in 2000. Among liver-related deaths, hepatocellular carcinoma increased from 15% to 25% (p=0.04). Among hepatocellular carcinoma-related deaths: in 2000, 10% were HCV-infected; in 2005, 25% were HCV-infected (p=0.03). Half of the HCV-related deaths had been treated for HCV but 98% remained HCV-RNA positive at time of death. The proportion of HBV-related deaths remained stable between 2000 and 2005. CONCLUSIONS: Liver-related deaths, mainly liver cancers, have increased in HIV-infectedpatients in France despite wide access to HCV treatment. The stability of HBV-related deaths might be explained by the use of dually active antiretroviral drugs in co-infected patients.
Authors: Mark Hull; Pierre Giguère; Marina Klein; Stephen Shafran; Alice Tseng; Pierre Côté; Marc Poliquin; Curtis Cooper Journal: Can J Infect Dis Med Microbiol Date: 2014 Impact factor: 2.471
Authors: C William Wester; John R Koethe; Bryan E Shepherd; Samuel E Stinnette; Peter F Rebeiro; Aaron M Kipp; Hwanhee Hong; Hermann Bussmann; Tendani Gaolathe; Catherine C McGowan; Timothy R Sterling; Richard G Marlink Journal: AIDS Date: 2011-07-31 Impact factor: 4.177
Authors: Marc-Arthur Loko; Dominique Salmon; Patrizia Carrieri; Maria Winnock; Marion Mora; Laurence Merchadou; Stéphanie Gillet; Elodie Pambrun; Jean Delaune; Marc-Antoine Valantin; Isabelle Poizot-Martin; Didier Neau; Philippe Bonnard; Eric Rosenthal; Karl Barange; Philippe Morlat; Karine Lacombe; Anne Gervais; François Rouges; Alain Bicart See; Caroline Lascoux-Combe; Daniel Vittecoq; Cécile Goujard; Claudine Duvivier; Bruno Spire; Jacques Izopet; Philippe Sogni; Lawrence Serfaty; Yves Benhamou; Firouzé Bani-Sadr; François Dabis Journal: BMC Infect Dis Date: 2010-10-22 Impact factor: 3.090